20n Bio is an artificial intelligence (AI)-powered drug discovery company focusing on designing new proteins for therapeutics.
20n Bio's mission is to address unmet medical needs by leveraging artificial intelligence to generate protein drugs in silico with desired biophysical, functional, and pharmacological properties.
20n Bio was founded in Sept 2021 by Mingfu Zhu. The company is headquartered in Malvern, PA.
20n's core technologies integrate advanced algorithms and high-throughput in vitro technologies to design protein binders with desired biophysical, functional, and pharmacological properties that interact with drug targets of interest.
20n Bio has raised $3.3M in a Seed funding on Dec 17, 2021. The round was led by BlueRun Ventures China.